Shahad W. Kattan

Dr. Shahad W. Kattan

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
SKShahad W. Kattan
Shahad W. Kattan
MNMohamed S. Nafie
Mohamed S. Nafie
GEGamal A. Elmgeed
Gamal A. Elmgeed
WAWalla Alelwani
Walla Alelwani
MBMuhammad Badar
Muhammad Badar
MTMohamed Tantawy
Mohamed Tantawy

19 January 2022 in Oncogenesis
Verified
Journal Article
Open access
PDF file
RBRoya Babaei-Jadidi
Roya Babaei-Jadidi
HKHossein Kashfi
Hossein Kashfi
WAWalla Alelwani
Walla Alelwani
ABAshkan Karimi Bakhtiari
Ashkan Karimi Bakhtiari
SKShahad W. Kattan
Shahad W. Kattan
ANAbdolrahman Shams Nateri
Abdolrahman Shams Nateri
Little is known about the role of microRNAs (miRNAs) in rewiring the metabolism within tumours and adjacent non-tumour bearing normal tissue and their potential in cancer therapy. This study aimed to investigate the relationship between deregulated miRNAs and metabolic components in murine duodenal polyps and non-polyp-derived organoids (mPOs and mNPOs) from a double-mutant ApcMinFbxw7∆G mouse model of intestinal/colorectal cancer (CRC). We analysed the expression of 373 miRNAs and 12 deregulated metabolic genes in mPOs and mNPOs. Our findings revealed miR-135b might target Spock1. Upregulation of SPOCK1 correlated with advanced stages of CRCs. Knockdown of miR-135b decreased the expression level of SPOCK1, glucose consumption and lactic secretion in CRC patient-derived tumours organoids (CRC tPDOs). Increased SPOCK1 induced by miR-135b overexpression promoted the Warburg effect and consequently antitumour effect of 5-fluorouracil. Thus, combination with miR-135b antisense nucleotides may represent a novel strategy to sensitise CRC to the chemo-reagent based treatment.

1 August 2021 in Pharmacogenomics and Personalized Medicine
Verified
Journal Article
Open access
PDF file
HMHala Mohammad
Hala Mohammad
AAAhmed A Abdelghany
Ahmed A Abdelghany
EAEssam Al Ageeli
Essam Al Ageeli
SKShahad W. Kattan
Shahad W. Kattan
RHRanya Moustafa Hassan
Ranya Moustafa Hassan
NMNaglaa Mokhtar
Naglaa Mokhtar
Background: Long non-coding RNAs (lncRNAs) play essential roles in molecular diagnosis and therapeutic response in several diseases. Purpose: For the first time, we aimed to evaluate the association of four lncRNAs TUG1 (rs7284767G/A), MIAT (rs1061540T/C), MALAT1 (rs3200401C/T), and SENCR (rs12420823C/T) variants with susceptibility to diabetic retinopathy (DR), disease severity, and early therapeutic response to intravitreous anti-vascular endothelial growth factor aflibercept therapy. Patients and Methods: This case-control study enrolled 126 adult patients with type 2 diabetes. TaqMan assays using Real-Time PCR were run for genotyping. Multivariable regression analyses were applied to assess the role of each polymorphism after the adjustment of covariates. Results: Carriers of TUG1 A/G and MIAT T/C and C/C genotypes were more likely to develop DR [OR=3.15 (95% CI=1.15– 8.64), and OR=4.31 (95% CI=1.78– 10.47)], while MALAT1 T/C conferred protection (OR=0.40, 95% CI=0.16– 0.99). For TUG1, MALAT1, MIAT, and SENCR genotype combinations, GTCT and GCCC had a higher disease risk (P=0.012). For disease severity, MIAT T/T homozygosity was associated with higher DR grade [33.3% (T/T) vs 10% (C/C) and 4.2% (C/T) carriers, P=0.012]. Otherwise, patients with the SENCR T variant exhibited better pre-treatment best-corrected visual acuity level (p=0.021). Following aflibercept administration, carrying the TUG1 A or MIAT T/C was associated with a poor therapeutic response (OR=5.02, 95% CI=1.60– 15.76, and OR=10.23, 95% CI=1.51– 69.15, respectively). Conclusion: The lncRNAs TUG1 (rs7284767G/A) and MIAT (rs1061540T/C) were associated with increased DR susceptibility and poor response to aflibercept treatment, while MALAT1 (rs3200401C/T) conferred protection to DR. These genetic determinants could be useful in DR risk stratification and pharmacogenetics after validation in large-scale studies.

1 November 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
ETEman Toraih
Eman Toraih
MHMohamed Hussein
Mohamed Hussein
EAEssam Al Ageeli
Essam Al Ageeli
MEMohamad Ellaban
Mohamad Ellaban
SKShahad W. Kattan
Shahad W. Kattan
EKEmad Kandil
Emad Kandil
Matrix metalloproteinase 9 (MMP9) and microRNA-145 (miR-145) have emerged as essential biomarkers in thyroid cancer progression and metastasis. However, their combined evaluation and clinical utility as a unified prognostic marker across diverse thyroid cancer subgroups remain unexplored. We investigated the diagnostic and prognostic value of the MMP9/miR-145 ratio in thyroid cancer, hypothesizing it may overcome inter-patient heterogeneity and serve as a versatile biomarker regardless of genetic mutations or autoimmune status. MMP9 and miR-145 expressions were analyzed in 175 paired papillary thyroid cancer (PTC) and normal tissues. Plasma levels were assessed perioperatively and longitudinally over 12–18 months in 86 matched PTC patients. The associations with clinicopathological parameters and patient outcomes were evaluated. MMP9 was upregulated, and miR-145 downregulated in cancer tissues, with a median MMP9/miR-145 ratio 17.6-fold higher versus controls. The tissue ratio accurately diagnosed thyroid malignancy regardless of BRAF mutation or Hashimoto’s thyroiditis status, overcoming genetic and autoimmune heterogeneity. A high preoperative circulating ratio predicted aggressive disease features, including lymph node metastasis, extrathyroidal extension, progression/relapse, and recurrence. Although the preoperative plasma ratio was elevated in patients with unfavorable outcomes, it had limited utility for post-surgical monitoring. In conclusion, the MMP9/miR-145 ratio is a promising biomarker in PTC that bridges genetic and immunological variabilities, enhancing preoperative diagnosis and prognostication across diverse patient subgroups. It accurately stratifies heterogenous cases by aggressiveness. The longitudinal trends indicate decreasing applicability for post-thyroidectomy surveillance. Further large-scale validation and protocol standardization can facilitate clinical translation of the MMP9/miR-145 ratio to guide personalized thyroid cancer management.


1 July 2019 in Russian Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
MTMuhammad Babar Taj
Muhammad Babar Taj
ARA. Raheel
A. Raheel
WAW. Alelwani
W. Alelwani
NBN. Babteen
N. Babteen
SKShahad W. Kattan
Shahad W. Kattan
HAH. B. M. Ali
H. B. M. Ali
Ten N( N′)-arylbenzamidines were synthesized in 60–77% yield by one-pot microwave-assisted reaction of the corresponding N-arylbenzamides with aniline or ammonia in the presence of copper(II) oxide...